2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Bois, Andreas du; Quinn, Michael; Thigpen, Tate; Vermorken, Jan B.; Åvall‐Lundqvist, Elisabeth; Bookman, Michael A.; Bowtell, David D.L.; Brady, Mark F.; Casado, Antonio; Cervantes, Andrés; Eisenhauer, E. A.; Friedlaender, Mitchell H.; Fujiwara, Keiichi; Grénman, Seija; Guastalla, Jean‐Paul; Harper, P.; Högberg, Thomas; Kaye, Stan B.; Kitchener, Henry C; Kristensen, Gunnar B.; Mannel, Robert S.; Meier, W.; Miller, Brigitte; Neijt, J.P.; Oza, Amit M.; Ozols, Robert F.; Parmar, Mahesh; Pecorelli, Sërgio; Pfisterer, Jacobus; Poveda, A.; Provencher, Diane; Pujade-Lauraine, Éric; Randall, Marcus E.; Rochon, Justine; Rustin, G. J. S.; Sagae, Satoru; Stehman, Frederick B.; Stuart, Gavin; Trimble, Edward L.; Vasey, P; Vergote, Ignace; Verheijen, René H.M.; Wagner, Uwe

doi:10.1093/annonc/mdi961

Cited by 391 publications

(233 citation statements)

References 4 publications

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…The high mortality rate is mainly due to advanced stage disease at initial diagnosis. Primary tumor debulking (cytoreduction) followed by chemotherapy is considered the standard of care for patients with advanced stage epithelial ovarian cancer (EOC) [2]. As an alternative to this practice, some authors have investigated the use of neoadjuvant chemotherapy followed by debulking surgery.…”

Section: Introductionmentioning

confidence: 99%

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy

Mhawech‐Fauceglia

Wang

Samrao

et al. 2013

Cancer Microenvironment

View full text Add to dashboard Cite

Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy

Mhawech‐Fauceglia

Wang

Samrao

et al. 2013

Cancer Microenvironment

View full text Add to dashboard Cite

show abstract

“…Based on NCCN, 2013, recommendation is referral of all adnexal mass patients to gyneco-oncologists (du Bois et al, 2005;Giede et al, 2005;Earle et al, 2006). Referral of all cases of adnexal mass takes high cost due to travel of many patients in order to be operated by Gyneco-oncologists in far or near tertiary medical centers.…”

Section: Discussionmentioning

confidence: 99%

“…So, if all adnexal masses are operated by tertiary medical centers and gyneco-oncologists as recommended by National Comprehensive Cancer Network (NCCN) guides (du Bois et al, 2005, Earle et al, 2006, Giede et al, 2005, these centers might be crowded by patients in the waiting list for surgery. Referral and prediction of malignancy criteria based on the region of practice is mentioned (Yavuzcan et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Ovarian Malignancy Probability Score (OMPS) for Appropriate Referral of Adnexal Masses

Arab

Honarvar²,

Hosseini-Zijoud³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Ovarian cancer is the most common cancer cause of gynecologic cancer deaths. In order to increase the likelihood of patient survival through primary operation by gyneco-oncologists, an appropriate algorithm for referral is considered here. Materials and Methods: Suspicious adnexal mass cases including ovarian malignancy probability score-1 (OMPS1) scores between 2.3-3.65 are re-evaluated by OMPS2. Sensitivity and specificity of each score were determined. Results: Sensitivity and specificity with a 3.82 score of OMPS2 in the studied subgroup (OMPS1 scores between 2.3-3.65) were 64% and 76.9% respectively. Conclusions: Management of OMPS1 scores of below 2.3 with sensitivity of 100% and above 3.65 with specificity of 72.9% is clear. In the subgroup of cases with OMPS1 score between 2.3-3.65, OMPS2 is helpful for triage with a cutoff score of 3.82.

show abstract

“…GOG-172, GOG-114 [18] as well as the NCI alert may overestimate the benefit of IP therapy in this group of patients. There has been no prospective randomized trial comparing IP therapy with intravenous (IV) carboplatin/ paclitaxel, which is universally recognized as the standard of care against which all new treatment regimens should be compared [41].…”

Section: Alternative Perspectives Of the Benefit Of Ip Therapymentioning

confidence: 99%

“…In a recent consensus conference of clinical investigators from cooperative groups throughout the world, carboplatin/paclitaxel was recognized as the standard of care against which all new treatments should be compared [41]. There has been no IP regimen that has been directly compared with IV carboplatin/paclitaxel.…”

Section: Alternative Perspectives Of the Benefit Of Ip Therapymentioning

confidence: 99%

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Alberts

Markman²,

Fm³

et al. 2006

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a third phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on Intraperitoneal Therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop.

show abstract

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Cited by 391 publications

References 4 publications

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy

Ovarian Malignancy Probability Score (OMPS) for Appropriate Referral of Adnexal Masses

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Contact Info

Product

Resources

About